Literature DB >> 11970789

Blindsight after optic nerve injury indicates functionality of spared fibers.

Stefan Wüst1, Erich Kasten, Bernhard A Sabel.   

Abstract

Some patients with lesions in the geniculostriate pathway (GSP) can respond to visual stimuli in the blind field without conscious acknowledgement. The substrate for this "blindsight" is controversial: whether it is the uninjured extrastriate pathway (EXP), which bypasses the lesion site, or residual fibers within damaged visual cortex ("islands of vision"). Using stimulus detection, localization, and spatial summation tasks, we have found blindsight in patients with damage both in the optic nerve (ON) and EXP. The prevalence and functional characteristics of their blindsight are indistinguishable from that in patients with GSP lesions, so blindsight does not require a completely intact EXP. The present findings support the view that a few surviving ON axons within an area of primary damage are sufficient to mediate blindsight: Several combinations of partially intact pathways can transmit information to the extrastriate cortex and the sum of activation of all visual fibers surviving the injury determines if and to what extent blindsight occurs.

Entities:  

Mesh:

Year:  2002        PMID: 11970789     DOI: 10.1162/089892902317236876

Source DB:  PubMed          Journal:  J Cogn Neurosci        ISSN: 0898-929X            Impact factor:   3.225


  3 in total

1.  Vision restoration therapy.

Authors:  B A Sabel; S Kenkel; E Kasten
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

2.  Passive auditory stimulation improves vision in hemianopia.

Authors:  Jörg Lewald; Martin Tegenthoff; Sören Peters; Markus Hausmann
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

3.  The second face of blindness: processing speed deficits in the intact visual field after pre- and post-chiasmatic lesions.

Authors:  Michał Bola; Carolin Gall; Bernhard A Sabel
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.